Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia

A. G. Villasante-Tezanos; C. Rohde; J. Nielsen; J. de Leon

doi:10.1111/acps.13184

Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia

A. G. Villasante-Tezanos
, C. Rohde
, J. Nielsen
, J. de Leon

Research output: Contribution to journal › Letter › peer-review

29 Scopus citations

Original language	English
Pages (from-to)	66-67
Number of pages	2
Journal	Acta Psychiatrica Scandinavica
Volume	142
Issue number	1
DOIs	https://doi.org/10.1111/acps.13184
State	Published - Jul 1 2020

Bibliographical note

Funding Information:
These analyses received no specific grant from any funding agency, commercial or not-for-profit sectors. The authors acknowledge Lorraine Maw, M.A., at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, who helped in editing this article.

Funding

These analyses received no specific grant from any funding agency, commercial or not-for-profit sectors. The authors acknowledge Lorraine Maw, M.A., at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, who helped in editing this article.

Funders
Lorraine Maw

Keywords

clozapine/adverse effects
clozapine/toxicity
infection
pneumonia
respiratory aspiration

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/acps.13184

Cite this

@article{c72d9bedc8ad4d40a619f63ec68c4d27,

title = "Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia",

keywords = "clozapine/adverse effects, clozapine/toxicity, infection, pneumonia, respiratory aspiration",

author = "Villasante-Tezanos, \{A. G.\} and C. Rohde and J. Nielsen and \{de Leon\}, J.",

note = "Funding Information: These analyses received no specific grant from any funding agency, commercial or not-for-profit sectors. The authors acknowledge Lorraine Maw, M.A., at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, who helped in editing this article.",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/acps.13184",

language = "English",

volume = "142",

pages = "66--67",

number = "1",

}

TY - JOUR

T1 - Pneumonia risk

T2 - approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia

AU - Villasante-Tezanos, A. G.

AU - Rohde, C.

AU - Nielsen, J.

AU - de Leon, J.

N1 - Funding Information: These analyses received no specific grant from any funding agency, commercial or not-for-profit sectors. The authors acknowledge Lorraine Maw, M.A., at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, who helped in editing this article.

PY - 2020/7/1

Y1 - 2020/7/1

KW - clozapine/adverse effects

KW - clozapine/toxicity

KW - infection

KW - pneumonia

KW - respiratory aspiration

UR - https://www.scopus.com/pages/publications/85088152705

UR - https://www.scopus.com/pages/publications/85088152705#tab=citedBy

U2 - 10.1111/acps.13184

DO - 10.1111/acps.13184

M3 - Letter

C2 - 32415875

AN - SCOPUS:85088152705

SN - 0001-690X

VL - 142

SP - 66

EP - 67

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

IS - 1

ER -

Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this